gft505 and Colitis

gft505 has been researched along with Colitis* in 1 studies

Other Studies

1 other study(ies) available for gft505 and Colitis

Article	Year
Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. European journal of medicinal chemistry, 2021, Jul-05, Volume: 219 NLRP3 inflammasome activation plays a critical role in inflammation and its related disorders. Herein we report a hit-to-lead effort resulting in the discovery of a novel and potent class of NLRP3 inflammasome inhibitors. Among these, the most potent lead 40 exhibited improved inhibitory potency and almost no toxicity. Further mechanistic study indicated that compound 40 inhibited the NLRP3 inflammasome activation via suppressing ROS production. More importantly, treatment with 40 showed remarkable therapeutic effects on LPS-induced sepsis and DSS-induced colitis. This study encourages further development of more potent inhibitors based on this chemical scaffold and provides a chemical tool to identify its cellular binding target. Topics: Animals; Anti-Inflammatory Agents; Cell Line; Chalcones; Colitis; Disease Models, Animal; Drug Design; Female; Inflammasomes; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Reactive Oxygen Species; Sepsis; Structure-Activity Relationship	2021

Article

Year

Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities.

European journal of medicinal chemistry, 2021, Jul-05, Volume: 219

NLRP3 inflammasome activation plays a critical role in inflammation and its related disorders. Herein we report a hit-to-lead effort resulting in the discovery of a novel and potent class of NLRP3 inflammasome inhibitors. Among these, the most potent lead 40 exhibited improved inhibitory potency and almost no toxicity. Further mechanistic study indicated that compound 40 inhibited the NLRP3 inflammasome activation via suppressing ROS production. More importantly, treatment with 40 showed remarkable therapeutic effects on LPS-induced sepsis and DSS-induced colitis. This study encourages further development of more potent inhibitors based on this chemical scaffold and provides a chemical tool to identify its cellular binding target.

Topics: Animals; Anti-Inflammatory Agents; Cell Line; Chalcones; Colitis; Disease Models, Animal; Drug Design; Female; Inflammasomes; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Reactive Oxygen Species; Sepsis; Structure-Activity Relationship

2021